Abstract:Background: CD40 receptor is a member of the tumor necrosis factor receptor family that plays a prominent role in immune responses. TQB2916, a humanized IgG2 CD40 monoclonal antibody, has demonstrated CD40 agonistic activity and promising anti-tumor activity in preclinical studies. A first-in-human study of TQB2916 single agent in advanced solid tumors and lymphomas is ongoing (NCT05213767). Methods: Patients with an ECOG performance status of 0 or 1, adequate hematologic and organ function and refractory to standard therapies met inclusion criteria. TQB2916 was given intravenously every 3 weeks until progression or unacceptable toxicity. Bayesian optimal interval (BOIN) design was used to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). The objective is to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TQB2916. Results: From April 2022 to November 2023, 18 patients with solid tumors and 2 with lymphoma have been treated with TQB2916 monotherapy, and were assigned to 7 cohorts (0.5 mg n=1, 2.5 mg n=1, 12.5 mg n=3, 60 mg n=3, 200 mg n=7, 300 mg n=2, and 400 mg n=3). Three dose limiting toxicities (DLTs) were observed: one with grade 3 pneumonia and one with grade 4 lipase/amylase increase in the 400 mg cohort; one with grade 3 pancreatitis in the 300 mg cohort. All patients experienced at least one treatment-related adverse event (TRAE). The most common TRAEs were lipase increase (n=15, 75%), amylase increase (n=14, 70%), lymphocyte count decrease (n=13, 65%), alanine aminotransferase (ALT) increase (n=12, 60%), alkaline phosphatase (ALP) increase (n=12, 60%), aspartate aminotransferase (AST) increase (n=11, 55%), hypoalbuminemia (n=11, 55%), and anorexia (n=11, 55%). Serious TRAEs occurred in 5 (25%) patients. Most of TRAEs were of grade 1 or grade 2 and manageable. Sixteen patients were evaluated for efficacy, and 3 of them achieved stable disease as per immune response evaluation criteria in solid tumors (iRECIST) and lymphoma response to immunomodulatory therapy criteria (LYRIC). The pharmacokinetics were well-behaved with increasing exposure dose-proportionally and no accumulation occurred after repeated dosing. The Cmax, AUC(0-t) and T1/2 of 400 mg single dosing were 109±21.8 μg/ml, 611±228 d*μg/mL and 5.54±3.37 d. Dose-dependent occupancy of CD40 was detected of 0.5 mg and above doses. Reduction in peripheral B cells and increasing in cytokines secretion were also observed. Conclusions: Pharmacodynamics analysis suggested that TQB2916 treatment achieved CD40 occupancy and immune activation with the changes in cytokines. Considering the safety profile and efficacy, 200 mg was determined as the preliminary expansion dose as it was well tolerated. Studies of TQB2916 in combination with immune checkpoint inhibitors and/or other anti-cancer therapies are ongoing. Citation Format: Yi Ba, Huilai Zhang, Ting Deng, Tao Ning, Qian Fan. A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr CT192.

Pharmacokinetics and immunogenicity of T0001, a newly developed anti-TNFα fusion protein, in healthy volunteers

Safety And Tolerability Of A Single Dose T0001 In Chinese Healthy Adult Volunteers: A First-In-Human Ascending Dose Study

T0001, a Variant of TNFR2-Fc Fusion Protein, Exhibits Improved Fc Effector Functions Through Increased Binding to Membrane-Bound TNFα

Effects of recombinant fusion protein of human tumor necrosis factor receptor mutant and Fc fragment for injection on the plasma concentration of tumor necrosis factor-α in Chinese healthy volunteers

Tolerability, safety, and pharmacokinetics of a single intravenous administration of a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody in healthy Chinese volunteers

A Phase 1, First-in-human, Open-Label, Dose Escalation and Dose Expansion Study of TST005 in Patients with Locally Advanced or Metastatic Solid Tumors

A Randomized Controlled Dose-Escalation Study of SSS07, a Humanized Rabbit Anti-Human TNF Alpha Antibody, in Healthy Chinese Adults.

Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody TQC2731 targeting thymic stromal lymphopoietin (TSLP) in healthy Chinese adults.

P633 First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma Patients

Recombinant Human Tumor Necrosis Factor Receptor Type Ⅱ - IgG Fc Fusion Protein for the Treatment of Moderate to Severe Psoriasis Vulgaris:A Multicenter, Randomized, Parallel-Group, Controlled Clinical Trial

Clinical Study of Single-Dose of Recombinant Humanized Anti-Cd3 Monoclonal Antibody Injection in Kidney Transplant Recipients

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers

Anti-drug antibodies of tumor necrosis factor alpha monoclonal antibody injection in Chinese healthy adult volunteers and analysis its influence factors

Prospective, multicenter clinical study of rmhTNF-NC injection in the treatment of Chinese malignant pleural effusion or peritoneal effusion patients

MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation

A First-in-human, Phase I, Dose-Escalation Study to Evaluate Pharmacokinetics, Safety, and Tolerability of KD6001, a Novel Anti-Ctla-4 Monoclonal Antibody (mab) in Patients with Advanced Solid Tumors.

Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects

Abstract CT192: A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies

Efficacy and Safety of a Novel Recombinant Human Tumor Necrosis Factor-Α Receptor Ⅱ : Fc Fusion Protein in Chinese Patients with Active Ankylosing Spondylitis: Results of a Randomized, Double-Blind,multicenter Trial

Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-?, in patients with advanced tumors

First-in-human Study of GFH018, a Small Molecule Inhibitor of Transforming Growth Factor-Β Receptor I Inhibitor, in Patients with Advanced Solid Tumors